Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 11, 2020 10:35 ET | Source: Glyscend Therapeutics

Glyscend Therapeutics Completes $20.5M Financing Round to Advance Novel Oral Polymer Therapy for Type 2 Diabetes

–Patient-Friendly Therapy Designed to Mimic the Dramatic Metabolic Benefits of Bariatric Surgery ––Company Aims to Begin First-in-Human Trials in Australia Next Year –Karen Talmadge, PhD, Industry...